Evidence map›Paper›PMID 38713593›Full record

ArticleEmerging microbes & infections2024

ZMapp reduces diffusion of Ebola viral particles in fresh human cervicovaginal mucus.

Alison Schaefer, Bing Yang, Holly A Schroeder, Dimple Harit, Mike S Humphry, Larry Zeitlin, Kevin J Whaley, Jacques Ravel, William A Fischer, Samuel K Lai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Emerging microbes & infections, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alison SchaeferUNC/NCSU Joint Department of Biomedical Engineering, Chapel Hill, NC, USA.
Bing YangDivision of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Holly A SchroederDivision of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Dimple HaritDivision of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Mike S HumphryInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA.
Larry ZeitlinMapp Biopharmaceutical, Inc., San Diego, CA, USA.
Kevin J WhaleyMapp Biopharmaceutical, Inc., San Diego, CA, USA.
Jacques RavelInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA.
William A FischerDivision of Pulmonary and Critical Care Medicine, School of Medicine, Chapel Hill, NC, USA.
Samuel K LaiDivision of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Funding

North Carolina Translational & Clinical Sciences Institute (NC TraCS)UL1TR001111 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, CAREY, TIMOTHY S · 2013 to 2017
$43.9M
North Carolina Translational and Clinical Sciences Institute (NC TraCS)UM1TR004406 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI NICHOLAS J SHAHEEN · 2023 to 2026
$37.5M
Serologic Biomarkers of Human Sexually Transmitted Infection and DiseaseU19AI084044 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI TETTELIN, HERVE S · 2009 to 2018
$22.8M
Clinical Sequelae and Urogenital Viral Dynamics in Survivors of Ebola Virus DiseaseK23AI121516 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI FISCHER, WILLIAM · 2016 to 2019
$783k
Trapping HIV in mucus with IgG antibodiesR21AI093242 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LAI, SAMUEL · 2011 to 2012
$403k
NCATS NIH HHS UL1 TR001111NCATS NIH HHS UM1 TR004406NIAID NIH HHS K23 AI121516NIAID NIH HHS R21 AI093242NIAID NIH HHS U19 AI084044
6 · The paper itself

Abstract

Vaginal transmission from semen of male Ebola virus (EBOV) survivors has been implicated as a potential origin of Ebola virus disease (EVD) outbreaks. While EBOV in semen must traverse cervicovaginal mucus (CVM) to reach target cells, the behaviour of EBOV in CVM is poorly understood. CVM contains substantial quantities of IgG, and arrays of IgG bound to a virion can develop multiple Fc-mucin bonds, immobilizing the IgG/virion complex in mucus. Here, we measured the real-time mobility of fluorescent Ebola virus-like-particles (VLP) in 50 CVM specimens from 17 women, with and without ZMapp, a cocktail of 3 monoclonal IgGs against EBOV. ZMapp-mediated effective trapping of Ebola VLPs in CVM from a subset of women across the menstrual cycle, primarily those with

Indexed as

EbolavirusHemorrhagic Fever, EbolaVaginaAdultCervix MucusFemaleHumansImmunoglobulin GMucusVirionImmunoglobulin GAntibodyEbolaImmunoglobulin G (IgG)microbiomemucinmucosal barrier

Identifiers

PMID38713593
PMCPMC11100441

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.